Internal Medicine, Medical Oncology · Clackamas, OR
NPI
1508869140
Since 2005
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
6
Medicare group memberships
Hospitals
3
Hospital affiliations
9280 SE Sunnybrook Blvd Ste 200
Clackamas, OR, 97015
Phone (503) 513-1900
Groups this clinician bills Medicare through
Medicare paid, 2024
$37K
708 services
Medicare patients, 2024
176
Average age 74
Drug cost, 2024
$3.0M
1,243 prescriptions
Company payments, 2025
$1,012
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Janet C Ruzich was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 285 times for 140 patients. In total Janet C Ruzich billed 708 services in 16 codes, and Medicare paid $37K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-01-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 285 | 140 | $12.85 | $3,662 |
| 99214 Office E&M - Established | Facility | 143 | 85 | $68.53 | $9,800 |
| 99215 Office E&M - Established | Facility | 111 | 34 | $112.18 | $12K |
| 99213 Office E&M - Established | Facility | 101 | 73 | $45.17 | $4,562 |
| 99205 Office E&M - New | Facility | 29 | 29 | $139.95 | $4,059 |
| 99204 Office E&M - New | Facility | 11 | 11 | $70.93 | $780 |
By year: 2022 $41K for 3,483 services; 2023 $41K for 1,661 services; 2024 $37K for 708 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 32 | 27 | $8.40 | $269 |
| 36415 Venipuncture Blood Collection | 22 | 15 | $8.40 | $185 |
| 85025 Blood Count | 22 | 17 | $7.61 | $167 |
| 84165 Clinical Chemistry | 19 | 15 | $13.17 | $250 |
Medicare prescription drug claims, 2024
In 2024, the drug Janet C Ruzich prescribed most often to Medicare patients was Anastrozole, with 182 prescriptions and refills. In total Janet C Ruzich wrote 1,243 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 182 | 389 | 52 | $2,502 |
| Tamoxifen Citrate Generic | 61 | 124 | 16 | $1,580 |
| Letrozole Generic | 55 | 91 | 16 | $619 |
| Prochlorperazine Maleate Generic | 55 | 55 | 33 | $723 |
| Dexamethasone Generic | 52 | 52 | 24 | $348 |
| Prednisone Generic | 48 | 50 | 17 | $291 |
| Oxycodone Hcl Generic | 40 | 40 | 17 | $519 |
| Eliquis Apixaban | 38 | 48 | 11 | $29K |
| Calquence Acalabrutinib Maleate | 29 | 29 | Under 11 | $428K |
| Ondansetron Hcl Generic | 28 | 28 | 20 | $180 |
| Olanzapine Generic | 27 | 31 | 15 | $176 |
| Hydroxyurea Generic | 25 | 37 | Under 11 | $622 |
| Brukinsa Zanubrutinib | 24 | 24 | Under 11 | $265K |
| Imatinib Mesylate Generic | 23 | 23 | Under 11 | $2,524 |
| Alendronate Sodium Generic | 23 | 61 | 11 | $173 |
Brand drugs: 239 claims; generic drugs: 1,004 claims; opioid claims: 112.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Janet C Ruzich $1,012 ($1,012 in general payments such as food, travel and fees) from 3 companies. The largest payer was Novartis Pharmaceuticals Corporation with $897.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.